A comparative observational study of fetomaternal outcome in gestational hypertension cases in coronavirus disease 2019 versus noncoronavirus disease 2019 patients
Background Coronavirus disease 2019 (COVID-19) which primarily involves the pulmonary system can also cause systemic involvement by panvascular endothelial dysfunction. Gestational hypertension is a systemic disease of maternal endothelial dysfunction which can progress to preeclampsia, eclampsia, a...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-10-01
|
| Series: | MRIMS Journal of Health Sciences |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/mjhs.mjhs_10_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background
Coronavirus disease 2019 (COVID-19) which primarily involves the pulmonary system can also cause systemic involvement by panvascular endothelial dysfunction. Gestational hypertension is a systemic disease of maternal endothelial dysfunction which can progress to preeclampsia, eclampsia, and multi-organ failure. Both the entities: COVID-19 and preeclampsia appeared to have camouflaged scenarios ultimately, presenting as endothelial dysfunction.
Objective
The present study aimed to estimate the number of COVID-19 and non-COVID-19 patients with gestational hypertension developing preeclampsia and their fetomaternal outcome in the third trimester.
Materials and Methods
It was a comparative observational study conducted in the Department of Obstetrics and Gynecology at Gandhi Hospital, Secunderabad, over a period of 18 months during the COVID-19 pandemic. One hundred women diagnosed with gestational hypertension were considered and their maternal and fetal complications were studied. They were divided into two groups based on the history of symptomatic COVID-19 infection and the COVID-19 reverse transcription–polymerase chain reaction (RT-PCR) report.
Results
The incidence of severe preeclampsia was more in the gestational hypertension with COVID-19 group (60%) when compared to the non-COVID-19 group (36%) (P = 0.016). The incidence of maternal deaths in the gestational hypertension with COVID-19 group was 20% (P = 0.08). Incidence of intrauterine growth restriction was 20% (P = 0.205) and neonatal deaths was 14% (P = 0.538) in the gestational hypertension with COVID-19 group.
Conclusion
Preeclampsia and COVID-19 infection during pregnancy were closely related with each other. In a synergistic fashion, COVID-19 infection with preeclampsia increases the risk of adverse maternal and perinatal outcomes. |
|---|---|
| ISSN: | 2321-7006 2321-7294 |